Thus, ISCA2 inhibition decreases HIF-α levels and induces the lipid peroxidation associated with ferroptosis both in vitro and in vivo and is a promising treatment strategy for ccRCC. The gene discussed is ISCA2; the disease is nonpapillary renal cell carcinoma.